HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Effects of estrogen and selective estrogen receptor modulators on osteoporosis].

Abstract
Evidence indicates that estrogen and raloxifene hydrochloride, a selective estrogen receptor modulator, prevent bone loss and reduce the risk of bone fractures in postmenopausal women. However, recent reports indicate that the health risks associated with the use of estrogen, which include breast cancer and coronary heart disease (CHD), exceed the benefits. In contrast, raloxifene is associated with a lower incidence of breast cancer and is not associated with CHD. Therefore, the use of raloxifene is preferable for the prevention and treatment of osteoporosis in postmenopausal patients.
AuthorsTomohiko Urano
JournalClinical calcium (Clin Calcium) Vol. 15 Issue 4 Pg. 591-5 (Apr 2005) ISSN: 0917-5857 [Print] Japan
PMID15802770 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Estrogens
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
Topics
  • Breast Neoplasms (chemically induced)
  • Coronary Disease (chemically induced)
  • Estrogen Replacement Therapy (adverse effects)
  • Estrogens (deficiency, physiology)
  • Evidence-Based Medicine
  • Female
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal (etiology, prevention & control)
  • Raloxifene Hydrochloride (administration & dosage)
  • Randomized Controlled Trials as Topic
  • Selective Estrogen Receptor Modulators (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: